Centivax, a developer of universal flu and other vaccines, has raised $37 million in follow-on funding for its next-generation flu protection. The funding comes as experts warn of challenges in building a vaccine company due to the current FDA structure. Centivax's CEO, Jake Glanville, also highlighted the challenge facing vaccine companies.